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Long lasting debates in the past questioned the relevance of any sort of compatibility in
post mortal kidney transplantation. It is for no say that fully compatible transplants have
the highest chances for a long patient and graft survival. In the present report the use
of HLA-DR as a representative of the Major Histocompatibility Complex class II genes in
the allocation of organs is discussed. The major arguments are the easiness to offer to
patients a compatible graft in a relatively short waiting time, an increase in graft survival,
the less sensitization during the transplantation period, and the lower waiting time for a
retransplant. Even if the number of organ donors remains the same a lowering of the mean
waiting time is expected because of the longer period of graft survival.
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INTRODUCTION
The role of HLA compatibility as a parameter for allocation of
kidneys from deceased donors to patients on the kidney waiting
list remains a matter of debate. It is well accepted that the best
possible organ for an end stage renal disease patient is a fully HLA
compatible kidney. The arguments of those acting against com-
patibility do not follow scientiﬁc criteria. Both graft and patient
survival in post mortal kidney transplantation are signiﬁcantly
better in compatible groups compared to kidneys transplanted
with incompatibilities (Doxiadis et al., 2004; Kaneku and Terasaki,
2006; Opelz and Döhler, 2007; Johnson et al., 2010). The same
holds true for kidneys from living donors (Opelz, 1997). Further-
more, HLA incompatible organs are the source of HLA antigens
toward which the patient can, even under immunosuppressive
therapy, form alloantibodies. Following the rules of Immunol-
ogy this step is triggered by the patients own HLA system. These
alloantibodies are currently suggested to be the main cause of
graft destruction (Sijpkens et al., 1999). Furthermore, incompat-
ibilities render the patient (highly) sensitized and after primary
graft loss more difﬁcult to be offered a suitable donor kidney for
retransplantation. Alloantibodies have been related not only to
acute but especially to chronic allograft dysfunction, better dis-
cussed as chronic rejection. Intervening therapies are used to treat
patients with alloantibodies such as intravenous immunoglobu-
lines (Glotz et al., 1993; Gebel and Halloran, 2010), anti-CD20
monoclonal antibodies recognizing the B cells and proteasome
inhibitors as Bortezomib (Trivedi et al., 2010). The results are not
always satisfactory. Prevention of alloantibody formation would
be a good alternative to the unsatisfactory treatment, which in the
case of transplantation results often into secondary problems like
degenerative diseases such as cancer (Opelz and Döhler, 2010).
HLA-DR COMPATIBILITY
Manymostly European organ exchange organizations allocate kid-
neys on the basis of HLA matching by giving more points to
better matched patients than those with a lower matching degree
(Doxiadis et al., 2004; Johnson et al., 2010). A selection of a spe-
ciﬁc locus, e.g., HLA-DR, is not yet the rule. Earlier it has been
shown that HLA-DR compatibility leads to an increased graft
survival for patients receiving a primary graft. The effect of HLA-
A, B compatibility disappears when patients receive a HLA-DR
incompatible organ (Doxiadis et al., 2007). These results have
been obtained using a large number of transplant (N = 35,205)
in the transplantation period of 1985–2005. In a follow-up study
retransplants were analyzed (Doxiadis et al., 2010). For the same
period as shown above post mortem kidney retransplants were
selected. The recipients were ≥18 years old while the donors were
over 5 years old. Transplants performed via special Eurotransplant
programs were excluded. End point of this analysis was graft loss
censored for death with functioning graft. Kaplan–Meier product
limit method was used to estimate survival rates. For the estima-
tion of relative risks (hazard ratios) for different variables Cox
proportional hazard regression was used. Adjusted survival curves
were plotted using the same procedure. All analyses were per-
formed with the SPSS statistical package, version 14 (SPSS Inc.,
Chicago, IL, USA). The course of post transplantation follow-up
was analyzed in the three separate phases post transplantation:
initial (<1 year), intermediate (≥1 to <5 years), and late phase
(≥5 years follow-up).
The results of these analyses are similar to the ones obtained
for the primary transplants. The effect of HLA-A, B compatibility
exists as expected over time and mimics the results already shown
for primary transplants. By introducing an HLA-DR incompati-
bility the effect of HLA-A, B compatibility disappears (Doxiadis
et al., 2010).
The risk factors in multivariate analysis showed that donor age
already reported for the primary grafting and also in many other
studies and sensitization degree of the patient at transplantation
are deleterious for the patient. Finally, HLA-A, B incompatibil-
ity is an independent factor resulting in a higher graft loss in the
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ﬁrst phase (≤1 year) post transplantation, presumably because of
alloantibodies or unreported earlier sensitization of the patients.
These results are based on a seroequivalent HLA-DR typing
(DR1–DR18) or a molecular typing of the ﬁrst ﬁeld, according to
the new nomenclature. In a simulation study we could show that
even on a local basis it is possible to offer to almost all patients
on the waiting list a fully HLA-DR compatible organ even includ-
ing patients of different genetic background, allowing an equitable
allocation to all patients on the waiting list.
The production of alloantibodies toward incompatibilities of
the donor is related to the MHC class II compatibility. In case
patients receive incompatible HLA-DR organs they have a sig-
niﬁcantly higher chance to produce alloantibodies against the
donor than in the case of compatible grafts (Doxiadis et al., 2007).
Many studies have been reported since the seminal publication of
Terasaki (2003) regarding the production of alloantibodies toward
the graft and its relation to transplantation. If one admits that
these alloantibodies affect allograft survival then prevention of
their formation might be the answer since selective elimination is
impossible to date.
The alloantibody prevention scenario for future transplant
might look as follows:
As a ﬁrst step patients are offered a fully HLA-DR (DRB1) com-
patible graft. Epitopes leading to alloantibody formation should
be avoided, e.g., Bw4 in HLA-DR1 or DR3 recipients (Fuller and
Fuller, 1999). After this initial phase full compatibility also for
other than HLA-DRB1 speciﬁcities should be aimed.At present no
conclusive data for any effect of HLA-DRB3,4,5 in large registries
are available, the same holds true for HLA-DQ. The very strong
associations between most of the HLA-DRB1 alleles to HLA-DQ
speciﬁcities make this type of analyses difﬁcult and require large
data sets, which are currently not available. The HLA phenotype
of the patient will lead to the selection of organs with a low chance
of alloantibody formation. The patients should be closely mon-
itored with respect to alloantibody production, e.g., monthly at
the initial phase of up to 6 months, and then at intervals of about
6 months, for two reasons: ﬁrst, for possible treatment and sec-
ond for data collection in order to fully understand alloantibody
formation under transplantation circumstances. The ﬁnal step
in this scenario would be to offer every patient a graft with the
least chances for HLA alloantibody formation (Duquesnoy et al.,
2003).
The proposed scenario would offer the following beneﬁts:
1. Increased graft and patient survival.
2. A signiﬁcant decrease of the sensitization toward donor HLA
incompatibilities during the transplantation period and, in case
of organ loss, more, and better possibilities for retransplanta-
tion.
3. Decrease of waiting time for the retransplant.
4. Reduced incidence of side effects, normally associated with
the additional immunosuppressive regiments necessary to treat
rejection episodes.
This proposal is only the ﬁrst step needed to reduce allosensitiza-
tion of patients receiving a kidney allograft. It is our intention to
introduce on the long term additional steps such as compatibility
of epitopes leading to alloantibodies. It is essential to reproduce
the data mentioned at the beginning of this review using local or
regional transplantation outcome, since controversial results have
been reported (e.g., Gritsch et al., 2008).
CONCLUSION
All patients should receive a fullyHLA-DRcompatible graft, result-
ing in an increased graft survival and reduced allosensitization.
SUMMARY
“Until immunosuppressive regiments are directed toward the
humoral component of graft rejection simple prevention should
be aimed in the ﬁeld of post mortal kidney transplantation.”
Alloantibodies are not only a relevant factor before transplantation
but are also a cause of allograft dysfunction after transplantation.
Full compatibility for MHC class II together with intelligent intro-
duction of incompatibilities could be seen as a ﬁrst step in a series
of possibilities to diminish allosensitization without the need of
additional immunosuppressive treatments.
AUTHOR NOTE
In kidney transplantation it is important to note that by eliminat-
ing the one component of the immune system other components
can take over. Until now the T cells were quoted as the “bad” guys.
In the present period B cells took over. Recently, we showed that
NK cells (van Bergen et al., 2011) are associated with graft loss
in the later period of transplantation (Gritsch et al., 2008). The
future will show what we should do.
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